Circulating tumor cell enumeration by the CellSearch system: The clinician's guide to breast cancer treatment?

Cancer Treatment Reviews

Volumn 41, Issue 2, 2015, Pages 144-150

  Beije, Nick ^a   Jager, Agnes ^a   Sleijfer, Stefan ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Circulating tumor cells; Clinical decision making; CTC; Recommendations

Indexed keywords

BIOLOGICAL MARKER; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; TUMOR ANTIGEN; TUMOR MARKER; TUMOR-ASSOCIATED ANTIGEN GA733;

BIOASSAY; BLOOD FLOW; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER PATIENT; CELL COUNT; CELLSEARCH ASSAY; CIRCULATING TUMOR CELL; CLINICAL DECISION MAKING; FEMALE; HUMAN; PRIMARY TUMOR; REVIEW; ADJUVANT THERAPY; BLOOD; BREAST NEOPLASMS; CELL SEPARATION; CLINICAL TRIAL (TOPIC); DEVICES; PATHOLOGY; PROCEDURES; TUMOR EMBOLISM;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL COUNT; CELL SEPARATION; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASTIC CELLS, CIRCULATING; TUMOR MARKERS, BIOLOGICAL;

EID: 84921636121     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.12.008     Document Type: Review

References (48)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Ignatiadis M., Riethdorf S., Bidard F.C., Vaucher I., Khazour M., Rothe F., et al. International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res 2014, 16:R43.
3. Tibbe A.G., Miller M.C., Terstappen L.W. Statistical considerations for enumeration of circulating tumor cells. Cytometry A 2007, 71:154-162.
4. Allard W.J., Matera J., Miller M.C., Repollet M., Connelly M.C., Rao C., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897-6904.
5. Kraan J., Sleijfer S., Strijbos M.H., Ignatiadis M., Peeters D., Pierga J.Y., et al. External quality assurance of circulating tumor cell enumeration using the CellSearch((R)) system: a feasibility study. Cytometry B Clin Cytom 2011, 80:112-118.
6. Sieuwerts A.M., Kraan J., Bolt J., van der Spoel P., Elstrodt F., Schutte M., et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009, 101:61-66.
7. Bednarz-Knoll N., Alix-Panabieres C., Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev 2012, 31:673-687.
8. Mostert B., Kraan J., Sieuwerts A.M., van der Spoel P., Bolt-de Vries J., Prager-van der Smissen W.J., et al. CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Lett 2012, 319:49-55.
9. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative G.
10. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
11. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
12. Arpino G., Generali D., Sapino A., Del Matro L., Frassoldati A., de Laurentis M., et al. Gene expression profiling in breast cancer: a clinical perspective. Breast 2013, 22:109-120.
13. Carlson J.J., Roth J.A. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat 2013, 141:13-22.
14. Kaufmann M., von Minckwitz G., Mamounas E.P., Cameron D., Carey L.A., Cristofanilli M., et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012, 19:1508-1516.
15. Pierga J.-Y.Y., Bidard F.-C.C., Mathiot C., Brain E., Delaloge S., Giachetti S., et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008, 14:7004-7010.
16. Bidard F.C., Belin L., Delaloge S., Lerebours F., Ngo C., Reyal F., et al. Time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-month analysis of the REMAGUS02 study. Int J Breast Cancer 2013, 2013:130470.
17. Riethdorf S., Muller V., Zhang L., Rau T., Loibl S., Komor M., et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010, 16:2634-2645.
18. Giordano A., Giuliano M., De Laurentiis M., Arpino G., Jackson S., Handy B.C., et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012, 23:1144-1150.
19. Peeters D.J., van Dam P.J., Van den Eynden G.G., Rutten A., Wuyts H., Pouillon L., et al. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Br J Cancer 2014, 110:375-383.
20. Wallwiener M., Hartkopf A.D., Baccelli I., Riethdorf S., Schott S., Pantel K., et al. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 2013, 137:503-510.
21. Pierga J.Y., Petit T., Delozier T., Ferrero J.M., Campone M., Gligorov J., et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012, 13:375-384.
22. Pierga J.Y., Petit T., Levy C., Ferrero J.M., Campone M., Gligorov J., et al. Circulating tumor cell count at baseline is an independent prognostic value from pathological complete response among patients treated for primary inflammatory HER2-positive breast cancer: survival results of the BEVERLY-2 study. Ann Oncol 2014, 25(Supplement 4):iv110-iv115. doi:101093/annonc/mdu3282.
23. Onstenk W., Kraan J., Charehbili A., Mostert B., Smit V.T.H.B.M., Kroep J.R. A combined EpCAM and MCAM circulating tumor cell (CTC) Cell Search enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOG) side study. J Clin Oncol 2013, 31. (suppl; abstr e22106).
24. Sandri M.T., Zorzino L., Cassatella M.C., Bassi F., Luini A., Casadio C., et al. Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann Surg Oncol 2010, 17:1539-1545.
25. Biggers B., Knox S., Grant M., Kuhn J., Nemunatitis J., Fisher T., et al. Circulating tumor cells in patients undergoing surgery for primary breast cancer: preliminary results of a pilot study. Ann Surg Oncol 2009, 16:969-971.
26. Lucci A., Hall C.S., Lodhi A.K., Bhattacharyya A., Anderson A.E., Xiao L., et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012, 13:688-695.
27. Franken B., de Groot M.R., Mastboom W.J., Vermes I., van der Palen J., Tibbe A.G., et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res 2012, 14:R133.
28. Karhade M., Hall C., Mishra P., Anderson A., Kuerer H., Bedrosian I., et al. Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat 2014, 147:325-333.
29. Rack B., Schindlbeck C., Jückstock J., Andergassen U., Hepp P., Zwingers T. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 2014, 106.
30. Coumans F.A., Ligthart S.T., Uhr J.W., Terstappen L.W. Challenges in the enumeration and phenotyping of CTC. Clin Cancer Res 2012, 18:5711-5718.
31. Buyse M., Loi S., van't Veer L., Viale G., Delorenzi M., Glas A.M. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006, 98:1183-1192.
32. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
33. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
34. Bidard F.C., Peeters D.J., Fehm T., Nole F., Gisbert-Criado R., Mavroudis D., et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014, 15:406-414.
35. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
36. Lin N.U., Thomssen C., Cardoso F., Cameron D., Cufer T., Fallowfield L., et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast 2013, 22:203-210.
37. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
38. Robinson A.G., Booth C.M., Eisenhauer E.A. Progression-free survival as an end-point in solid tumours - perspectives from clinical trials and clinical practice. Eur J Cancer 2014, 50:2303-2308.
39. Budd G.T., Cristofanilli M., Ellis M.J., Stopeck A., Borden E., Miller M.C., et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006, 12:6403-6409.
40. De Giorgi U., Valero V., Rohren E., Dawood S., Ueno N.T., Miller M.C., et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 2009, 27:3303-3311.
41. Smerage J.B., Barlow W.E., Hortobagyi G.N., Winer E.P., Leyland-Jones B., Srkalovic G. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014, 32:3483-3489.
42. Bidard F.-C.C., Fehm T., Ignatiadis M., Smerage J.B., Alix-Panabières C., Janni W., et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 2013, 32:179-188.
43. Bidard F.C., Baffert S., Hajage D., Brain E., Armanet S., Simondi C. Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial. Cancer Res 2012, 72.
44. Bidard F.C., Asselain B., Baffert S., Brain E., Delaloge S., Bachelot T. Use of early CIRculating tumor CElls count changes to guide the use of chemotherapy in advanced metastatic breast cancer patients: the CirCe01 randomized trial. Cancer Res 2012, 72.
45. Onstenk W., Gratama J., Foekens J., Sleijfer S. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics. Cancer Treat Rev 2013, 39:691-700.
46. Dutch Trial Registry: "CTC-cDDP study" . http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4046.
47. CareMoreCTC studies. http://www.caremorectc.eu/.
48. Yu M., Bardia A., Aceto N., Bersani F., Madden M.W., Donaldson M.C., et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014, 345:216-220.